THRM Q2 2026 Earnings Call Summary

Gentherm (THRM) Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: $416 million, up 11% year-over-year, exceeding expectations.
Adjusted EBITDA: $48.8 million (11.7% of sales), down from 12.2% in Q2 2025.
Adjusted Diluted EPS: $0.75, a 39% increase from $0.54 in Q2 2025.
Free Cash Flow: Approximately $16 million year-to-date, consistent with expectations.
Net Leverage: 0.3 turns with liquidity of $502 million.
New Business Awards: Secured $690 million in Q2, totaling over $1 billion year-to-date.

2. Strategic Updates and Business Highlights

Market Expansion: Gentherm is diversifying beyond automotive, securing contracts with two major North American furniture brands, projecting $50 million to $100 million in revenue from this sector by 2028.
Medical Innovations: Received FDA 510(k) clearance for ThermAffyx, a new patient warming solution, with initial sales expected in Q3 2026.
Acquisition: Completed the acquisition of Innovative Medical Equipment (IME) for $34 million, enhancing Gentherm's capabilities in non-opioid thermal therapy.
Merger with Modine Performance Technologies: Expected to close in early Q4 2026, anticipated to diversify Gentherm's portfolio and reduce reliance on light vehicle markets from 97% to approximately 63%.

3. Forward Guidance and Outlook

2026 Revenue Guidance: Raised to a midpoint of $1.6 billion, representing approximately 5% growth despite a projected 3% decline in light vehicle production.
Adjusted EBITDA Guidance: Expected between $185 million and $200 million, with a midpoint margin of around 12%.
Adjusted Free Cash Flow: Estimated between $85 million and $100 million for the year.
Long-term Outlook: Targeting over $3.5 billion in revenue by 2030, with significant cash flow generation anticipated.

4. Bad News, Challenges, or Points of Concern

Profitability Pressure: Adjusted EBITDA margin decreased year-over-year due to inflation recovery timing and increased warranty accruals.
Warranty Accruals: Higher claims related to a specific automotive product, although management does not expect this to continue as improvements have been made.
Market Uncertainty: Some caution regarding the second half of 2026 due to potential headwinds from runoff businesses and tougher year-over-year comparisons.

5. Notable Q&A Insights

Core Automotive Business: Strong performance across various regions and product categories, with confidence in maintaining mid-single-digit growth over market trends.
IME Acquisition Synergies: Significant cross-selling opportunities identified, particularly with access to Veterans Administration hospitals, which Gentherm previously did not serve.
ThermAffyx Demand: Strong initial interest and market demand noted, with clinical trials underway.
Future Guidance: Management remains cautious about updating 2027 revenue guidance but expresses confidence in achieving at least $1.7 billion.

Overall, Gentherm demonstrated solid execution in Q2 2026, with strong financial performance and strategic initiatives aimed at diversifying its market presence while navigating some operational challenges.

THRM — Gentherm Incorporated